One-year outcomes of bioresorbable magnesium scaffold implantation in complex coronary lesions.
Simon Wölbert, Thomas Schmidt, Fabian Wittek...
https://pubmed.ncbi.nlm.nih.gov/42368841/Actively Recruiting
Led by Biotronik AG · Updated on 2025-11-21
1106
Participants Needed
13
Research Sites
N/A
Total Duration
Researchers are monitoring the clinical performance and short-term safety of Resorbable Magnesium Scaffolds RMS used in patients with symptomatic coronary artery disease. This registry follows the ESCEACTS guideline and observes RMS use in real-world settings without additional medical exclusion criteria beyond the devices intended instructions for use. The devices studied include Magmaris and Freesolve, both designed to improve the luminal diameter in the treatment of new native coronary artery lesions. The scaffold size is matched to the vessel diameter, and lesion length is limited to the scaffold length. The study collects data on these devices as they are used according to their approved instructions. Participants will be followed to assess the primary outcome of Target Lesion Failure within 12 months after device implantation. The registry collects clinical information during routine care to evaluate device performance and safety over time. The study started in November 2020 and will continue through May 2030.
CONDITIONS
Resorbable Magnesium Scaffolds Registry
M
Marina Gattiglio, Dr.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Biotronik AG
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Varies according to individual treatment schedules
Participants undergo treatment with resorbable magnesium scaffolds as part of routine care for coronary artery disease.
Duration - Up to 12 months
Participants who undergo routine care are observed for up to 12 months to assess treatment outcomes.
Approximately 1 to 2 visits during follow-up
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Simon Wölbert, Thomas Schmidt, Fabian Wittek...
https://pubmed.ncbi.nlm.nih.gov/42368841/Biotronik AG
Lead Sponsor